CJC-1295 Side Effects Reported in the Research Literature

CJC-1295 side effects documented in published studies and regulatory review documents include injection-site reactions, transient vasodilatory events, and downstream effects of elevated GH and IGF-1. The primary human pharmacokinetic study, Teichman et al. (2006), reported the compound was well tolerated at doses of 30–60 mcg/kg, with vasodilatory reactions — including flushing — occurring at higher doses (90–125 mcg/kg) ^[1]. No serious adverse reactions were documented at 30–60 mcg/kg in that trial.

In 2024, the FDA's Pharmacy Compounding Advisory Committee raised immunogenicity concerns for injectable CJC-1295 formulations, citing potential risks from peptide aggregation impurities in compounded preparations. The nomination for CJC-1295 to the FDA 503A Category 2 compounding list was subsequently withdrawn. CJC-1295 is not FDA-approved for any indication.

What Are the Reported Side Effects of CJC-1295?

Adverse events documented in published studies and clinical reports include:

Injection-site reactions: Erythema (redness), swelling, and local discomfort at the injection site are the most commonly reported adverse events across subcutaneous peptide injection studies.

Flushing and vasodilation: The Teichman 2006 trial noted transient vasodilatory reactions at the 90–125 mcg/kg dose level ^[1]. Flushing is attributed to vasodilatory effects of elevated GH and potentially to direct peptide-induced nitric oxide signaling.

Headache: Transient headache has been reported in clinical and observational data from subjects using CJC-1295 and related GHRH analogs.

Water retention: Elevated GH and IGF-1 influence renal sodium and water reabsorption, and water retention (edema) is a recognized effect of GH axis stimulation in the published endocrinology literature.

Elevated appetite: Increased hunger has been reported in observational data; the mechanism is consistent with elevated GH and IGF-1 signaling.

Joint discomfort: Carpal tunnel syndrome, joint pain, and swelling are documented adverse effects of supraphysiological GH elevation in the acromegaly literature and have been reported with GH secretagogue use.

Cardiovascular signals: Vasodilatory effects were specifically noted in FDA review documents in the context of cardiovascular considerations for CJC-1295.

Why Does CJC-1295 Cause Flushing?

Flushing is attributed to the vasodilatory effects of elevated GH and potentially to direct peptide-induced nitric oxide signaling in peripheral vasculature ^[1]. The Teichman 2006 trial noted transient vasodilatory reactions in human subjects at doses of 90–125 mcg/kg. The mechanism is believed to be analogous to niacin-flush pathways — peripheral vasodilation causing skin redness and warmth — with GH-mediated vasodilation as the primary driver. At lower doses (30–60 mcg/kg), this effect was not prominently reported.

CJC-1295 Safety Data in Published Research

Phase II human trials reported CJC-1295 to be well tolerated at doses of 30–60 mcg/kg in healthy adults ^[1]. The Ionescu and Frohman (2006) pulsatility study at 60–90 mcg/kg reported GH and IGF-1 elevation without documenting serious adverse events ^[3].

A Phase II clinical trial (NCT00267527) in HIV-infected patients with visceral obesity was halted in July 2006 following the death of one participant ^[18]. The cause of death and its relationship to the study drug was under investigation at the time of termination. The trial had enrolled 192 participants. No efficacy data from that trial have been published. This event is part of the CJC-1295 safety record and is documented at ClinicalTrials.gov.

In 2024, the FDA placed CJC-1295 on the 503A bulk drug substance no-go list, citing lack of clinical necessity demonstrating advantage over approved alternatives and immunogenicity concerns for injectable formulations related to potential peptide aggregation.

Risks and Adverse Events in CJC-1295 Peptide Research

Research on muscle-building and body composition applications of GH-axis peptides notes several theoretical risk categories with supraphysiological GH elevation:

Acromegaly-like effects: Chronic excess GH produces soft tissue overgrowth, skeletal changes, and metabolic disruptions including insulin resistance (acromegaly). CJC-1295 studies in rodents observed dose-dependent IGF-1 elevation without reported overt organ toxicity at standard research doses ^[5], but the acromegaly literature establishes these as long-term physiological risks of sustained GH excess.

Glucose metabolism: Elevated GH has anti-insulin effects and can impair glucose tolerance. No specific glucose metabolism adverse events were reported in the published CJC-1295 human trials, but the GH-axis biology predicts this as a monitoring concern.

Injection-site complications: Subcutaneous injection at any site carries risks of local infection, lipohypertrophy with repeated injection, and sterile abscess if preparation sterility is not maintained.

WADA prohibited status: CJC-1295 is classified as a prohibited substance under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) for competitive athletes, both in- and out-of-competition ^[17]. Detection methods for CJC-1295 in biological samples exist, though albumin conjugation complicates standard mass spectrometry workflows ^[17]^[19].

Does CJC-1295 Cause Hair Loss?

No published study has identified hair loss as a direct adverse event of CJC-1295. Elevated IGF-1 has theoretical associations with androgenic pathways in some models, but no clinical or preclinical data specifically links CJC-1295 to alopecia. Hair loss does not appear in the adverse event records of the Teichman 2006 or Ionescu 2006 human studies ^[1]^[3].